Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China

作者：Baolong Ding, Hongting Yao, Tiantian Tao, Yuyang Sun, Yulu Zhu, Haomin Zhu, Jia Wang, Zhuying Jing, Lihong Gao, Yingtao Lin, Xin Li · 发表于：Therapeutic Advances in Medical Oncology · 年份：2025 · DOI：10.1177/17588359251379708 · 被引用次数：5 · 研究领域：Renal cell carcinoma treatment、Economic and Financial Impacts of Cancer、Health Systems, Economic Evaluations, Quality of Life

Background: The LITESPARK-005 trial demonstrated the efficacy and safety of belzutifan in patients with previously treated clear cell renal cell carcinoma (ccRCC). This study aims to evaluate the cost-effectiveness of belzutifan compared to everolimus in treating patients with advanced ccRCC who have received at least one systemic therapy from the perspective of the Chinese healthcare system and the US payers. Objectives: To provide previously treated ccRCC patients with the option of belzutifan and to offer recommendations regarding in China. Design: The cost-effectiveness analysis. Methods: A partitioned survival model was constructed based on data from the LITESPARK-005 trial. Patients transitioned through three mutually exclusive health states: progression-free survival (PFS), progressive disease, and death. The model cycle length was set at 28 days, with a lifetime horizon. Direct medical costs and utility values were obtained from published literature and real-world healthcare data. The model estimated total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Price simulations, sensitivity analyses, and scenario analyses were conducted to assess model robustness. Results: The base-case analysis showed that belzutifan in China generated 2.038 QALYs at a total cost of $102,561.26 and an ICER of $54,430.16/QALY, which exceeded the willingness to pay (WTP) threshold ($39,076.44/QALY). Belzutifan in the United States generated 2.280...